Last reviewed · How we verify
MMR followed by YF
MMR vaccine primes immune response against measles, mumps, and rubella; yellow fever vaccine then boosts immunity against yellow fever virus.
MMR vaccine primes immune response against measles, mumps, and rubella; yellow fever vaccine then boosts immunity against yellow fever virus. Used for Prevention of measles, mumps, and rubella, Prevention of yellow fever.
At a glance
| Generic name | MMR followed by YF |
|---|---|
| Sponsor | Alba Maria Ropero |
| Drug class | Live attenuated viral vaccine combination |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
MMR is a live attenuated vaccine that stimulates cellular and humoral immunity against three viral pathogens. Yellow fever (YF) vaccine, also live attenuated, is administered sequentially to provide protection against yellow fever virus. The sequential administration may leverage cross-reactive immune responses or simply provide comprehensive coverage against both vaccine-preventable diseases.
Approved indications
- Prevention of measles, mumps, and rubella
- Prevention of yellow fever
Common side effects
- Injection site reaction (pain, erythema, swelling)
- Fever
- Rash
- Myalgia
Key clinical trials
- Immunogenicity of Co-administered Yellow Fever and Measles, Mumps, and Rubella (MMR) Vaccines (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MMR followed by YF CI brief — competitive landscape report
- MMR followed by YF updates RSS · CI watch RSS
- Alba Maria Ropero portfolio CI